President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.
Total Pharmacy
Latest News
Total Pharmacy Podcasts
All News
Advertisement
A conversation with Douglas Hoey, RPh, MBA, CEO of NCPA, on the chain pharmacy’s announcement of a second Chapter 11 bankruptcy.
In this episode of the podcast, Shawn and Jesse discuss how every situation has a solution and the best way to find it.
Antonio Ciaccia, President of 3 Axis Advisors, CEO of 46brooklyn Research, and pharmacy benefits expert, discusses the commonly circulated misconceptions about PBMs.
Douglas Hoey, CEO of NCPA, discusses what pharmacies can do to increase revenue and avoid shutting their doors.
A conversation with Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, clinical assistant professor and director of experiential learning at West Virginia University School of Pharmacy, at AAP 2025.
Expert on drug pricing and pharmacy benefits, Antonio Ciaccia joined Drug Topics to discuss how PBMs came to hold so much control of the pharmaceutical supply chain.
A conversation with Greg Mitchell, owner of United Drug Superstore in Hatch, New Mexico, at AAP 2025.
Luke Turnock, PhD, discusses the role of pharmacists and medication counselors in addressing the challenges of increased direct-to-consumer drug advertising on social media.
Researchers explored the confidence, barriers, and role of general practice independent pharmacists regarding prescribing services within primary care settings.
Advertisement
Antonio Ciaccia, President of 3 Axis Advisors, CEO of 46brooklyn Research, and pharmacy benefits expert, discusses litigious, market-based, and legislative reform for pharmacy benefit managers.
Researchers identified differences in naloxone training, policies, procedures, and preferences among chain or independent pharmacies across Alabama.
A discussion with Douglas Hoey, RPh, MBA, CEO of NCPA, at AAP 2025.
CVS releases a statement shortly after HB1150 was signed in Arkansas, prohibiting pharmacy benefit managers from owning pharmacies.
LucyRx is empowering pharmacists and impacting patients’ health outcomes with its business model unlike other market-leading pharmacy benefit managers.
The 14-section order focuses on a variety of policy changes intended to make patients’ out-of-pocket costs for prescription medications more affordable in the US.
At AAP 2025, Greg Mitchell, owner of United Drug Superstore, discussed how retail pharmacies can leverage vaccine services to build long-term patient relationships.
At AAP 2025, Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, discussed how Disney’s approach to customer service can be applied in a community pharmacy setting.
At AAP 2025, Douglas Hoey, RPh, MBA, CEO of NCPA, discussed what pharmacies can do to increase revenue and avoid shutting their doors.
At AAP 2025, Melanie Maxwell, president of AlignRx, discussed the intent, benefits and consequences of the IRA.
On behalf of 39 state and territory attorneys general, the National Association of Attorneys General issued a letter to Congress regarding major PBMs’ conflicts of interest.
Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, discusses effective strategies for balancing excellent patient care with strict regulations surrounding controlled substances.
David Blair, CEO of LucyRx, joined Drug Topics to discuss the initiatives his company is conducting in support of a struggling pharmacy profession.
At AAP 2025, Douglas Hoey, CEO of NCPA, discussed the possibility of PBM reform under the new administration and his take on Optum Rx’s plans to introduce a cost-plus reimbursement model.
In a telephone audit, researchers attempted to quantify the frequency of patient barriers when looking to purchase sterile syringes from community pharmacies for over-the-counter use.
First-in-class brensocatib has the potential to be the first approved treatment for bronchiectasis.
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Can Play Central Role in Patients’ Infusion Services | ASHP Midyear 2025
2
FDA Expands Approval of Flibanserin for Postmenopausal Women’s Sexual Health
3
Why Trump’s Second Term is Different for the MFN Drug Pricing Policy
4
FDA Approves Etripamil as First At-Home Option for Paroxysmal Supraventricular Tachycardia
5
